Palisade Bio, Inc. (PALI) Reports In-Line Q3 EPS

Palisade Bio, Inc. (NASDAQ: PALI) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Palisade Bio, Inc. (PALI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance